Kiniksa Pharmaceuticals reported fourth quarter 2024 ARCALYST net product revenue of $122.5 million, contributing to a full-year 2024 net product revenue of $417.0 million. This full-year figure represents a 79% increase over 2023, highlighting the continued commercial success of ARCALYST.
The company reiterated its 2025 ARCALYST net product revenue guidance, expecting sales to be between $560 million and $580 million. Kiniksa also expects to remain cash flow positive on an annual basis under its current operating plan.
Kiniksa announced plans to initiate a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data anticipated in the second half of 2026. Phase 1 single ascending dose data support the potential for monthly subcutaneous dosing of KPL-387 in a liquid formulation, offering a potential convenience advantage.
In a strategic shift, Kiniksa decided to discontinue the development of abiprubart in Sjögren’s Disease and is exploring strategic alternatives for the asset. This decision aligns with the company's prioritization of cardiovascular indications for its pipeline, focusing resources on assets with the highest perceived potential.
Since the launch of ARCALYST in 2021, Kiniksa has generated over $800 million in product revenue. The company aims to further increase its penetration into the recurrent pericarditis patient population with ARCALYST, leveraging its established market presence.
Kiniksa is also advancing KPL-1161, a pre-clinical Fc-modified IL-1R1 antibody, with a target profile of quarterly subcutaneous dosing. The company is currently engaging in IND-enabling development activities for this longer-term pipeline asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.